Abstract:BACKGROUND: The addition of PGM followed by doxorubicin/cyclophosphamide versus control was evaluated as neoadjuvant therapy. Here IGF-1R pathway based protein and phosphoprotein (p) biomarkers were examined for their predictive utility. METHODS: Reverse phase protein array evaluated 102 pretreatment PGM and 169 control HER2- specimens. 32 pre-specified biomarker candidates were examined. A logistic regression model adjusted for hormone receptor (HR) status. The Benjamini-Hochberg (BH) method adjusted for multiple hypothesis testing. ROC analysis identified dichotomizing thresholds for select biomarkers. RESULTS: In the entire PGM population in a model adjusting for HR status, higher levels of pIGF-1R (Y1135/Y1136)/IR (Y1150/Y1151) (OR=2.13 p<0.002; BH p<0.05) and lower levels of p27 T187 (OR= 0.41 p<0.002; BH p<0.05) were significantly associated with pCR. Downstream IGF-1R signaling proteins were nominally associated with pCR (IRS-1 S612, p90 RSK S380, FOXO1 T24/FOXO3a T32). In HR+ tumors (n=58), pIGF-1R retained its significant positive association with pCR (OR=4.08 P<0.002; LR p<0.05), with an AUC of 0.79 [95% CI: 0.56-1]. Using an optimal dichotomizing threshold, 16% (9/58) of HR+HER2- were classified pIGF-1R.IR-High; and 56% (5/9) of these patients achieved pCR vs. 6% (3/49) in the pIGF1R.IR-Low subset. In TN patients (n=44), pIGF-1R did not associate with response. However, lower pp27 remained nominally associated with higher pCR rates for PGM treatment (OR=0.42 p 0.05) with an AUC of 0.74 [95% CI: 0.58-0.89]; and when optimally dichotomized, 52% (13/25) of pp27 Low TN patients achieved pCR vs. 12% (2/17) in the pp27 High group. None of these PGM-response-predictive biomarkers associated with response in the control arm. Total receptor levels did not associate with response. CONCLUSION: We are the first to show that pre-treatment levels of IGF-1R protein pathway activation-based signaling phosphoproteins, including levels of pIGF-1R, the drug target for ganitumab, may be predictive biomarkers for drugs targeting this receptor especially in the HR+ subset. Citation Format: Emanuel F. Petricoin, Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Laura van 't Veer, Rosa I. Gallagher, Gillian L. Hirst, Lamorna Brown-Swigart, Laura J. Esserman, Douglas Yee. IGF-1R protein pathway activation is associated with pathologic complete response to an anti-IGF-1R regimen (paclitaxel, ganitumab, and metformin) in the I-SPY2 neoadjuvant breast cancer trial [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1) nr A019.

Pathway-specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway As a Novel Therapeutic Target in Cervical Cancer.

Data from Integrative Analysis Identifies a Novel AXL–PI3 Kinase–PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer

542 the Role and Mechanism of KMT2D to Modulate PI3Kα Inhibitor Response in Cervical Cancer Identified by CRISPR/Cas9 Genome-Wide Screening

The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy

F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial

[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors

Targeting PI3Kα increases the efficacy of anti-PD-1 antibody in cervical cancer

Phosphoinositide-3-kinase Inhibition Enhances Radiosensitization of Cervical Cancer in Vivo.

Targeting PI3K Increases the Efficacy of Anti-Pd-1 Antibody in Cervical Cancer

Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment

The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer

Abstract IA005: PET imaging predictors of response to chemoradiotherapy in cervical cancer

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Abstract A019: IGF-1R protein pathway activation is associated with pathologic complete response to an anti-IGF-1R regimen (paclitaxel, ganitumab, and metformin) in the I-SPY2 neoadjuvant breast cancer trial

Role of Phosphatidylinositol 3-Kinase and Its Catalytic Unit PIK3CA in Cervical Cancer: A Mini-Review

Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.

Expression of Megfr, Pegfr(Thr654), and Ppkn1(Thr774) to Predict Response to Chemoradiation and Prognosis in Patients with Cervical Cancer.

Prognostic and Predictive Value of Phospho-p44/42 and Pakt in HER2-positive Locally Advanced Breast Cancer Patients Treated with Anthracycline-Based Neoadjuvant Chemotherapy

Genetic Alterations of PIK3CA and Tumor Response in Patients with Locally Advanced Cervical Squamous Cell Carcinoma Treated with Cisplatin-Based Concurrent Chemoradiotherapy.

EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma

Phosphatidyl Inositol-3 Kinase (PIK3CA) E545K Mutation Confers Cisplatin Resistance and a Migratory Phenotype in Cervical Cancer Cells